This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of colon결장의 악성신생물 (결장암)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: C18 / Special Copayment Reduction: V193 / copayment 5% (for 5 years from the date of cancer registration)
B. SynonymsColon cancer, colorectal cancer (colon), colonic adenocarcinoma, Colon cancer, Colonic adenocarcinoma
C. Adult onsetVery high — increases sharply after age 50; early-onset colon cancer at age 50 or younger is also increasing
1. HistoryVogelstein adenoma-carcinoma model (1990), history of colonoscopic screening, molecular subtype classification, Korean national screening
2. CausesRed and processed meat, obesity, physical inactivity, alcohol, smoking, inflammatory bowel disease, hereditary syndromes
3. GeneticsVogelstein: APC→KRAS→SMAD4→TP53; BRAF·MLH1 (MSI-H); Lynch (MLH1·MSH2); FAP (APC); CMS classification
4. General epidemiologyMore than about 30,000 cases per year in Korea; ranks 1st–2nd in both men and women; 3rd in incidence worldwide; notable increase at age 50 or younger
5. PathophysiologyVogelstein multistep adenoma-carcinoma sequence, serrated pathway (BRAF·CIMP), Lynch MMR pathway
6. SymptomsBloody stools, change in bowel habits, abdominal pain, weight loss, anemia, abdominal mass, decreased stool caliber
7. SignsAbdominal mass, anemia, hepatomegaly, elevated CEA·CA19-9, digital rectal examination, ascites
8. ScreeningNational screening: annual fecal occult blood test from age 50 → colonoscopy if positive; early endoscopy for high-risk groups
9. DiagnosisColonoscopy+biopsy, CT, PET-CT, CEA, TNM (AJCC 8th edition), RAS·BRAF·MMR·MSI·HER2 testing
10. TreatmentColectomy, FOLFOX·FOLFIRI+bevacizumab·cetuximab, pembrolizumab (MSI-H), BEACON (BRAF V600E)
11. Prognosis5-year survival rate: stage I 90%↑, stage II 75–85%, stage III 45–60%, stage IV 10–15%; MSI-H has a favorable prognosis
12. PreventionColonoscopic removal of adenomas, diet (dietary fiber·vegetables), weight management, smoking cessation, Lynch·FAP surveillance
13. ReferencesVogelstein B et al. Science 1988 and 9 other papers

1. History

The history of colon cancer (colorectal cancer, Colon cancer) began with the development of surgical techniques in the 19th century. In 1885, Reybard performed the first successful colectomy for colon cancer, and colorectal surgery subsequently became safe with advances in anesthesia, antisepsis, and blood transfusion. In the first half of the 20th century, Miles established abdominoperineal resection (APR) for rectal cancer, and the standard surgical principles for colorectal cancer were established. Radiation therapy and chemotherapy were introduced as adjuvant treatments for colorectal cancer from the late 20th century, and 5-FU (1957) became the basis of colorectal cancer chemotherapy.

In molecular genetics, in 1988–1990 Bert Vogelstein and Eric Fearon proposed the multistep carcinogenesis model (adenoma-carcinoma sequence) of colorectal cancer, showing that the sequential accumulation of mutations APC → KRAS → SMAD4 → TP53 drives progression from normal mucosa → adenoma → invasive adenocarcinoma. This was a historic study that changed the paradigm of cancer biology. Subsequently, the relationship between mismatch repair genes such as MLH1 and MSH2 and Lynch syndrome was established (1993–94), and the role of the APC gene in FAP patients was elucidated. With the proposal of the consensus molecular subtype (CMS) classification in 2012, the molecular heterogeneity of colorectal cancer was systematized.

In Korea, colorectal cancer was included in the National Cancer Screening Program in 2004, standardizing an annual fecal occult blood test (FOBT) from age 50 → colonoscopy if positive. As a result of this program, the early detection rate of colorectal cancer in Korea has continued to improve. Recently, immune checkpoint inhibitors (pembrolizumab, MSI-H colorectal cancer), BRAF-targeted therapy (encorafenib+binimetinib+cetuximab, BEACON trial), HER2-targeted therapy, and others have been introduced for the treatment of metastatic colorectal cancer.


2. Causes

The risk factors for colon cancer involve a combination of diet, lifestyle, and genetic factors. Numerous epidemiological studies have confirmed that intake of red meat and processed meat is associated with colon cancer risk, and processed meat has been classified by IARC as a Group 1 carcinogen. Proposed carcinogenic mechanisms of processed meat include the formation of N-nitroso compounds and oxidative damage from heme iron. Obesity increases colon cancer risk through insulin resistance, elevated insulin-like growth factor (IGF-1), and chronic inflammation. Physical inactivity is an independent risk factor, and there is meta-analytic evidence that regular exercise lowers colon cancer risk by 20–30%.

Alcohol causes DNA damage to the colorectal mucosa through acetaldehyde, a metabolite of alcohol, and impairs absorption of dietary folate. Smoking accelerates adenoma formation and carcinogenesis. Inflammatory bowel disease (IBD), especially ulcerative colitis, increases colon cancer risk 2–5 times compared with the general population through chronic colonic inflammation, and the risk is greater with longer disease duration and more extensive involvement. Diabetes independently increases colon cancer risk through insulin resistance. Lack of dietary fiber, low intake of vegetables and fruits, and a high-fat diet are also related risk factors.

As for genetic factors, the risk doubles when a first-degree relative has colon cancer. In Lynch syndrome (HNPCC), germline mutations of MMR genes (MLH1·MSH2·MSH6·PMS2) raise colon cancer risk to as much as 80%, and in familial adenomatous polyposis (FAP), APC gene mutations lead to colon cancer in almost 100% of cases if untreated. MUTYH-associated polyposis (MAP) is also a rare hereditary syndrome.


3. Genetics

The molecular genetics of colon cancer is classified into three main pathways, represented by Vogelstein's multistep carcinogenesis model. 1. Chromosomal instability (CIN) pathway (traditional adenoma-carcinoma sequence): progresses in the order APC mutation (loss of function) → activation of the Wnt/β-catenin pathway → adenoma formation → KRAS mutation (activation of the RAS-MAPK pathway) → 18q deletion (loss of SMAD4·DCC) → TP53 mutation → invasive adenocarcinoma. This pathway accounts for about 65% of colon cancers. Major mutations: APC (70–80%), KRAS (40–45%), TP53 (40–50%), SMAD4 (15%), PIK3CA (15–20%).

2. Mismatch repair deficiency (MMR)/MSI-H pathway: when MMR function is lost due to Lynch syndrome (germline MMR mutations) or sporadic MLH1 promoter methylation, replication errors accumulate. This pathway accounts for about 15% of colon cancers (sporadic about 12%, hereditary about 3%). MSI-H colon cancer has a high TMB and abundant neoantigens and responds excellently to immune checkpoint inhibitors. 3. Serrated pathway: BRAF V600E mutation → CIMP (CpG island methylator phenotype) → MLH1 methylation → MSI-H serrated polyp → colon cancer. Unlike the traditional adenoma pathway, this pathway has serrated polyps as precursor lesions.

Molecular subtypes (CMS): CMS1 (MSI-H immune, frequent BRAF mutations), CMS2 (traditional adenoma pathway, WNT·MYC activation), CMS3 (metabolic dysregulation, frequent KRAS mutations), CMS4 (mesenchymal, TGF-β, worst prognosis). Therapeutic target genes: anti-EGFR antibodies (cetuximab, panitumumab) are effective only in RAS (KRAS·NRAS) wild-type tumors. With BRAF V600E mutation, the BEACON regimen (encorafenib+binimetinib+cetuximab). In HER2 amplification (about 2–5%), trastuzumab+lapatinib (HERACLES trial). Hereditary syndromes: Lynch, FAP, MAP (MUTYH), PTEN hamartoma tumor syndrome (Cowden).


4. General epidemiology

Colon cancer (C18) is a very common cancer, with more than about 1.1 million cases annually worldwide, and a major cause of cancer-related death. In Korea, colon cancer + rectal cancer (all colorectal cancer) occurs in more than about 30,000 cases annually (as of 2022), ranking third after thyroid cancer and gastric cancer. C18 (colon cancer) occurs about twice as often as rectal cancer (C19–C20). Colorectal cancer is among the most common cancers in both men and women, and is about 1.5 times more common in men than in women. By age, it increases sharply after 50 and occurs most often in the 70s.

A notable feature of incidence trends is that early-onset colon cancer at age 50 or younger is increasing in both Western countries and Korea. Proposed causes include increasing obesity, lack of exercise, increased consumption of ultra-processed foods, and changes in the microbiome. Geographically, incidence is high in North America, Australia, and Western Europe, and it is also increasing rapidly in East Asia. Korea is one of the countries with the highest incidence of colorectal cancer in Asia, largely influenced by Westernized dietary habits. As a result of the national screening program, the early detection rate is increasing and mortality is improving.

Lynch syndrome accounts for about 2–3% of all colon cancers (about 600–900 cases per year in Korea), and FAP for about 0.5–1%. Universal MMR testing is recommended for the diagnosis of Lynch syndrome, and in Korea too, recommendations to perform MMR/MSI testing on all colon cancer patients are spreading.


5. Pathophysiology

The pathogenesis of colon cancer is explained by three main molecular pathways. Traditional adenoma-carcinoma pathway (Vogelstein model, CIN pathway): loss of function of the APC (adenomatous polyposis coli) gene is the initial event, resulting in sustained activation of the Wnt/β-catenin signaling pathway. This causes proliferative cells to overgrow and form an adenoma. Subsequently, KRAS mutation (sustained activation of the RAS-MAPK·PI3K-AKT pathways), 18q deletion (loss of SMAD4/DCC, weakened TGF-β signaling), and TP53 mutation (disruption of cell cycle checkpoints) accumulate sequentially, leading through high-grade dysplastic adenoma to invasive adenocarcinoma. This process takes about 10–15 years.

Serrated pathway (BRAF/CIMP): BRAF V600E mutation is the initial event, causing loss of MLH1 expression through CIMP methylation of the MLH1 promoter. This results in an MSI-H state, and tends to progress rapidly to cancer via sessile serrated adenoma/polyp (SSA/P). BRAF-mutant MSI-H colon cancer shows the irony of having a rather poor prognosis. MMR deficiency/MSI-H pathway (Lynch): loss of function of MMR genes (MLH1·MSH2, etc.) leads to accumulation of replication errors and instability of short repeat sequences (microsatellites). Numerous mutations accumulate rapidly, progressing to cancer. MSI-H colon cancer is very sensitive to immune checkpoint inhibition due to its abundant neoantigens.

The colonic microbiome has also been shown to be involved in colon cancer development. Mechanisms have been proposed by which specific bacteria such as Fusobacterium nucleatum and Bacteroides fragilis promote inflammation and cell proliferation in the colonic mucosa. The pathway by which obesity-insulin resistance-elevated IGF-1 promotes colonic mucosal cell proliferation is also included among the carcinogenic mechanisms.


6. Symptoms

A characteristic of colon cancer is that its symptoms differ according to tumor location (right vs. left colon). Right colon cancer (cecum, ascending colon, right half of the transverse colon): because the lumen in this area is wide and stool is liquid, the main symptom is anemia due to chronic bleeding (fatigue, dizziness, pallor) rather than obstructive symptoms. It often progresses asymptomatically and is found on anemia testing. A right lower quadrant mass may be palpable, or dull abdominal pain may appear. Left colon cancer (descending colon, sigmoid colon): because the lumen is narrow and stool is solid, the main symptoms are changes in bowel habits (alternating constipation and diarrhea, decreased stool caliber, sensation of incomplete evacuation) and bleeding with defecation (bright red blood in stools, bloody mucous stools). Obstructive symptoms (abdominal distension, abdominal pain, cessation of bowel movements) are also relatively common.

Common symptoms include weight loss, abdominal pain (cramping or persistent), fatigue (due to anemia), loss of appetite, and bloody stools (bright red blood or black stools). Colon cancer has a long asymptomatic initial period, so by the time symptoms appear it has often already advanced. This is why asymptomatic screening (fecal occult blood test, colonoscopy) is important. In people aged 50 or older with unexplained iron deficiency anemia, the right colon must be evaluated by colonoscopy. In young patients aged 40 or younger, rectal bleeding should not be regarded merely as hemorrhoids, and endoscopic evaluation should be performed.

Rarely, colon cancer first presents with symptoms of peritoneal dissemination or lung, liver, or bone metastasis, in which case the primary colon cancer is asymptomatic.


7. Signs

Physical findings of colon cancer differ by stage and location. In the early stage there are often no specific findings. In advanced colon cancer, an abdominal mass may be palpable. In right colon cancer, a hard mass is felt in the right lower or right upper quadrant, and in left colon cancer it is palpated in the left lower quadrant or lower abdomen. Abdominal distension, hyperactive bowel sounds (partial obstruction), and a tumor palpable on digital rectal examination may also be present. With peritoneal metastasis, ascites is observed, and hepatomegaly (liver metastasis).

As a systemic sign, anemia (conjunctival pallor, skin pallor) is prominent in right colon cancer, accompanied by hypoalbuminemia (malnutrition) and weight loss. Virchow's node (left supraclavicular lymphadenopathy) suggests distant lymph node metastasis. On blood tests, elevated CEA is the representative tumor marker for colon cancer and is used to confirm the preoperative baseline and for follow-up after treatment (low diagnostic specificity). CA19-9 may also be elevated as an adjunct. Liver function abnormalities (elevated ALP, GGT) suggest liver metastasis. Loss of MMR protein on IHC (any of MLH1·MSH2·MSH6·PMS2) or a positive PCR- or NGS-based MSI test indicates MSI-H and is important for treatment and prognosis. RAS (KRAS·NRAS), BRAF V600E, and HER2 testing are essential for selecting targeted therapy in metastatic colon cancer.


8. Screening

Korea's national colorectal cancer screening program adopts a two-step screening approach in which an annual fecal occult blood test (FOBT: fecal immunochemical test, iFOBT) is performed for men and women aged 50 and older, followed by colonoscopy if positive. The iFOBT detects human hemoglobin in stool with antibodies and is more sensitive than the conventional guaiac-based test (gFOBT), with no need for dietary restrictions. Domestic and international studies have confirmed that this national program significantly lowers colorectal cancer mortality.

Colonoscopy is the most sensitive and specific test, allowing colorectal cancer screening and removal of precancerous lesions (adenomas) at the same time. The guidelines of the Korean Society of Gastrointestinal Endoscopy recommend colonoscopic screening at 5–10-year intervals from age 50. In high-risk groups (family history of colon cancer, Lynch syndrome, FAP, ulcerative colitis for 10 years or more), colonoscopy is performed from an earlier age and at shorter intervals. Colonoscopy every 1–2 years from age 20–25 is recommended in Lynch syndrome, and annually from puberty in FAP. Stool DNA tests (Cologuard, etc.) have been approved in the United States but are not yet widely used in Korea. Liquid biopsy (ctDNA-based Guardant Shield, etc.) has received US FDA approval, but its introduction in Korea is under review. CT colonography (virtual colonoscopy) is used as an alternative in patients for whom endoscopy is not possible.


9. Diagnosis

Colon cancer is confirmed by colonoscopy + tissue biopsy. The entire colon is examined and biopsies are taken from suspicious lesions. If polyps are present, endoscopic resection (polypectomy) is performed immediately. For large lesions that cannot be resected endoscopically or lesions suspected to be cancer, sufficient biopsies are taken before surgery. After histological confirmation, testing for RAS (KRAS·NRAS) mutations, BRAF V600E, MMR protein IHC (or MSI PCR/NGS), HER2 IHC/FISH, and NTRK fusions is performed. All of these are essential for deciding the direction of treatment.

For staging, abdominal, chest, and pelvic CT is essential and is used to evaluate distant metastasis (liver, lung, peritoneum). PET-CT is used as a complement for evaluating distant metastasis or when CT findings are uncertain. When liver metastasis is present, contrast-enhanced liver MRI evaluates the number, size, and location of metastatic lesions more accurately. AJCC 8th edition TNM staging: T1 (mucosa to submucosa), T2 (muscularis propria), T3 (subserosal connective tissue), T4a (visceral peritoneum), T4b (adjacent organs). N0 (no metastasis), N1a (1), N1b (2–3), N1c (satellite nodule), N2a (4–6), N2b (7 or more). M1a (single organ), M1b (2 or more organs), M1c (peritoneum). CEA is measured as a pretreatment baseline and then used as a follow-up indicator.


10. Treatment

The curative treatment for colon cancer is surgical resection. Depending on the site, right hemicolectomy (cecum to transverse colon), left hemicolectomy, or sigmoid colectomy is performed. Minimally invasive surgery (laparoscopic, robotic) has become standard, with long-term survival equivalent to open surgery. Complete mesocolic excision (CME) + central vascular ligation (CVL) has been reported to maximize lymph node harvest and improve prognosis. For synchronous resectable liver metastases, colectomy and hepatectomy are performed simultaneously or in stages.

Adjuvant chemotherapy after surgery for stage III (lymph node metastasis): 6 months of FOLFOX (5-FU+Leucovorin+Oxaliplatin) or CAPOX (Capecitabine+Oxaliplatin) is standard. Adjuvant chemotherapy is also considered in high-risk stage II patients (T4, inadequate lymph node retrieval, perineural or vascular invasion, obstruction or perforation). First-line chemotherapy for metastatic (stage IV) colon cancer: FOLFOX or FOLFIRI combined with a biological targeted agent. RAS wild-type: cetuximab or panitumumab + chemotherapy improves OS. RAS-mutant or regardless of RAS status: bevacizumab (a VEGF antibody) + chemotherapy.

In BRAF V600E-mutant metastatic colon cancer, encorafenib+binimetinib+cetuximab, based on the BEACON trial, is approved as second-line or later treatment. In MSI-H/dMMR metastatic colon cancer, first-line monotherapy with pembrolizumab (KEYNOTE-177) showed superior PFS compared with chemotherapy and has become the standard. In HER2-positive colon cancer, trastuzumab+lapatinib (HERACLES) and trastuzumab+tucatinib (MOUNTAINEER) are being explored as later-line treatments. In resectable metastatic colon cancer, surgery with curative intent (hepatic/pulmonary metastasectomy) is performed selectively.


11. Prognosis

The prognosis of colon cancer varies greatly with stage at diagnosis. 5-year survival rate by stage: stage I about 90–93%, stage IIA about 85–87%, stage IIB about 72–75%, stage IIIA about 83%, stage IIIB about 64%, stage IIIC about 44%, stage IVA (single-organ metastasis) about 20–30%, stage IVB about 15–20%, stage IVC (peritoneal metastasis) about 5–10%. In Korea, the 5-year survival rate for all colorectal cancer (C18–C20) is 75–80% (National Cancer Center, 2016–2020), and survival is improving as the effect of screening has raised the early detection rate.

Molecular prognostic factors: MSI-H (favorable prognosis in stage II–III, no benefit from 5-FU alone as adjuvant therapy, excellent response to immunotherapy), BRAF V600E mutation (poor prognosis in stage IV), RAS mutation (resistance to anti-EGFR therapy, slightly poor prognosis), HER2 amplification (resistance to anti-EGFR therapy). During post-treatment follow-up, a rise in CEA above baseline suggests recurrence. Surgical margin status (R0/R1/R2) is the most important surgical prognostic factor. Peritoneal metastasis (M1c) has the worst prognosis compared with other distant metastases (M1a, M1b), and in selected cases cytoreductive surgery (CRS)+HIPEC shows a survival benefit.

Recurrence occurs mainly in the liver, lung, peritoneum, and regional lymph nodes and is most common in the first 2–3 years after surgery. Patients with Lynch syndrome need surveillance for metachronous colon cancer. A systematic surveillance program including CEA and CT follow-up for 5 years after completion of treatment is important for early detection of recurrence.


12. Prevention

The most effective and direct method of preventing colon cancer is endoscopic removal of colorectal adenomas. When adenomas (polyps) are found, immediate removal by endoscopic polypectomy can prevent colon cancer. For this reason, actively participating in national colorectal cancer screening (age 50 and older, fecal occult blood test→colonoscopy) is the most important preventive measure. Follow-up colonoscopy is recommended after 10 years if no adenoma is found on the first colonoscopy, after 5–10 years for low-risk adenomas (1–2, less than 1cm, tubular adenoma), and after 3 years for high-risk adenomas (3 or more, 1cm or larger, villous adenoma, high-grade dysplasia).

Dietary prevention: a diet rich in dietary fiber (vegetables, fruits, whole grains), minimal intake of red and processed meat, and sufficient intake of calcium and vitamin D are supported as lowering colon cancer risk. Preventing obesity and regular physical activity (moderate exercise of 150 minutes or more per week) lower colon cancer risk by 20–30%. Smoking cessation and moderation of alcohol also have supplementary preventive effects. There is evidence that aspirin and NSAIDs lower the risk of adenomas and colon cancer, but given the risk of gastrointestinal bleeding, preventive use in the general population is not recommended, and clinical studies are under way in specific high-risk groups (Lynch syndrome, FAP). In patients with Lynch syndrome and FAP, genetic counseling and surveillance programs are key. In FAP, prophylactic proctocolectomy or rectum-preserving total colectomy is recommended.


13. References

  1. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525-532.
  2. André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207-2218.
  3. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med. 2019;381(17):1632-1643.
  4. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356.
  5. Sargent DJ, Marsoni S, Thibodeau SN, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219-3226.
  6. National Cancer Center. Annual report of the 2022 Korea Central Cancer Registry. Ministry of Health and Welfare and National Cancer Center, 2024.
  7. van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-1422.
  8. Schmoll HJ, van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. Ann Oncol. 2012;23(10):2479-2516.
  9. Korean Society of Coloproctology. Clinical practice guidelines for colon cancer. Journal of the Korean Society of Coloproctology, 2023.
  10. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.